Maximising an attractive australian R&D landscape to commercialise the most promising advances in medical technology
M.H. Carnegie is targeting attractive medical device opportunities at the intersection of Australian innovation and the US distressed medical device market. We have a demonstrated track record of investing in cutting edge innovations in the sector and are looking to build on this success. We believe that Australia has a true competitive advantage in medical devices being a proven leader in the industry combined with a strong healthcare system and a strongly favourable tax environment to carry out research and development.
Our medical device platform is managed by a highly experienced leadership team led by Australian-based Mark Carnegie, who has over 30 years of experience as a global entrepreneur, investor and corporate adviser and US-based Trevor Moody, who has over 25 years of experience as an investor and operator in the medical technology industry.
|Date of Investment||December 2014|
|Deal Summary||Simplify is a medical device company that has developed an implantable cervical disc replacement to treat patients with degenerative disc disease of the spine. The Simplify Disc is a best-in-class cervical disc replacement designed to preserve natural motion and is the only cervical disc replacement designed to allow the full diagnostic imaging capability of MRI. This important feature eliminates the need for CT scans and reduces patient radiation exposure. The Simplify Disc is CE Mark approved in Europe and is currently the subject of two large clinical studies in the US. Co-investors in Simplify are leading global healthcare investors, Life Science Partners and Sectoral Asset Management|
|M.H. Carnegie lead the recapitalisation of Simplify in 2014 and has been instrumental in strategy, financing, corporate governance etc since then. Mark Carnegie and Trevor Moody are members of the Simplify board of directors|